Immunotherapy: will we reach a point where we can curatively treat advanced NSCLC?
The challenges of using biomarkers for immunotherapy
R. Donald Harvey
How to maximize clinical benefits for patients with ALK-positive non-small cell lung cancer
Patient care must be considered when using new anticancer drugs
Influence of new immunotherapy checkpoint inhibitors in melanoma